// App-Quantinova.ai

: Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Researchers

Presenter

  • Richard S. Finn

Principal Investigators

  • Shukui Qin

  • Masatoshi Kudo

  • Tim Meyer

  • Frederic Boisserie

  • Songzi Li

  • Yaxi Chen

  • Gisoo Barnes

  • Ramil Abdrashitov

  • Andrew X. Zhu

  • Arndt Vogel

Medical Centers

  • BeiGene Pharmaceuticals, Jenkintown, PA

  • Eastern Theater General Hospital of PLA, Nanjing, China

  • Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

  • Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA

  • BeiGene, Ridgefield Park, NJ

  • Department of Oncology, UCLH NHS Foundation Trust, London, United Kingdom

  • BeiGene, Ridgefield Park, NJ

  • BeiGene, Beijing, China

  • BeiGene USA Inc, Fulton, MD

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Jiahui International Cancer Center, Shanghai, China

Locations

  • United Kingdom

  • United States

  • China

  • Germany

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Tislelizumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03412773

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved